NeuroSoV is a biotech company focused on the discovery and development of cutting edge therapies targeted at slowing down the Parkinson Disease (PD), aiming to deliver the most effective and safe therapeutic and diagnostic solutions to slow-down/treat PD patients. Our ultimate goal is to deliver the most possible quality of life to PD patients and we work passionately to achieve it.
Our team developed a new drug candidate for PD, that targets an enzyme that contribute for the oxidative stress pathologic mechanism in PD. This approach has the potential to halt the progression of Parkinson's Disease. NeuroSoV also works on preclinical validation, both in vitro and in vivo, of molecules with therapeutic potential for Parkinson's disease, thus offering greater predictability of the therapeutic behavior of these molecules, thus anticipating better results in clinical trials.